APO Research
Talk to an analyst

APO RESEARCH · REPORT

Tumor Fluid Biopsy

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Tumor Fluid Biopsy Market Outlook and Growth Opportunities 2026

30 December 2025193 pages

Choose your research edition.

Industry ResearchTumor Fluid Biopsy Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Tumor Fluid Biopsy Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Tumor Fluid Biopsy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Tumor Fluid Biopsy Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Tumor Fluid Biopsy Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Tumor Fluid Biopsy market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Tumor Fluid Biopsy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Tumor Fluid Biopsy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Tumor Fluid Biopsy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Tumor Fluid Biopsy market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Tumor Fluid Biopsy market include Cellmax Life, Exact Science, Amoy Diagnostics Co, Berry Genomics Co, Genetronhealth, GenoploRare, HaploX Biotechnology Co, New Horizon Health Limited and Burning Rock Biotech, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Tumor Fluid Biopsy market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Tumor Fluid Biopsy and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Tumor Fluid Biopsy revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Tumor Fluid Biopsy market.

Tumor Fluid Biopsy Segment by Company

Cellmax Life

Exact Science

Amoy Diagnostics Co

Berry Genomics Co

Genetronhealth

GenoploRare

HaploX Biotechnology Co

New Horizon Health Limited

Burning Rock Biotech

Guangzhou Wondfo Biotech

YZY Biopharma

Tumor Fluid Biopsy Segment by Type

CTDNA Detection

CTC Detection

Other

Tumor Fluid Biopsy Segment by Application

Hospital

Third Party Organization

Other

Tumor Fluid Biopsy Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Tumor Fluid Biopsy status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Tumor Fluid Biopsy key companies, revenue, market share, and recent developments.

3. To split the Tumor Fluid Biopsy breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Tumor Fluid Biopsy market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Tumor Fluid Biopsy significant trends, drivers, influence factors in global and regions.

6. To analyze Tumor Fluid Biopsy competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tumor Fluid Biopsy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Tumor Fluid Biopsy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tumor Fluid Biopsy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Tumor Fluid Biopsy industry.

Chapter 3: Detailed analysis of Tumor Fluid Biopsy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Tumor Fluid Biopsy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Tumor Fluid Biopsy in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Tumor Fluid Biopsy Industry Trends Table 2. Tumor Fluid Biopsy Industry Drivers Table 3. Tumor Fluid Biopsy Industry Opportunities and Challenges Table 4. Tumor Fluid Biopsy Industry Restraints Table 5. Global Tumor Fluid Biopsy Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Tumor Fluid Biopsy Revenue Share by Company (2021-2026) Table 7. Global Tumor Fluid Biopsy Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Tumor Fluid Biopsy Key Company Manufacturing Base & Headquarters Table 9. Global Tumor Fluid Biopsy Company, Product Type & Application Table 10. Global Tumor Fluid Biopsy Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Tumor Fluid Biopsy by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of CTDNA Detection Table 15. Significant Companies of CTC Detection Table 16. Significant Companies of Other Table 17. Global Tumor Fluid Biopsy Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Tumor Fluid Biopsy Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Tumor Fluid Biopsy Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Tumor Fluid Biopsy Sales Value Share by Type (2021-2026) Table 21. Global Tumor Fluid Biopsy Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Hospital Table 23. Significant Companies of Third Party Organization Table 24. Significant Companies of Other Table 25. Global Tumor Fluid Biopsy Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Tumor Fluid Biopsy Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Tumor Fluid Biopsy Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Tumor Fluid Biopsy Sales Value Share by Application (2021-2026) Table 29. Global Tumor Fluid Biopsy Sales Value Share by Application (2027-2032) Table 30. Global Tumor Fluid Biopsy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Tumor Fluid Biopsy Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Tumor Fluid Biopsy Sales Value Share by Region (2021-2026) Table 33. Global Tumor Fluid Biopsy Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Tumor Fluid Biopsy Sales Value Share by Region (2027-2032) Table 35. Global Tumor Fluid Biopsy Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Tumor Fluid Biopsy Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Tumor Fluid Biopsy Sales Value Market Share by Country (2021-2026) Table 38. Global Tumor Fluid Biopsy Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Tumor Fluid Biopsy Sales Value Market Share by Country (2027-2032) Table 40. Cellmax Life Company Information Table 41. Cellmax Life Business Overview Table 42. Cellmax Life Tumor Fluid Biopsy Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Cellmax Life Tumor Fluid Biopsy Product Portfolio Table 44. Cellmax Life Recent Development Table 45. Exact Science Company Information Table 46. Exact Science Business Overview Table 47. Exact Science Tumor Fluid Biopsy Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Exact Science Tumor Fluid Biopsy Product Portfolio Table 49. Exact Science Recent Development Table 50. Amoy Diagnostics Co Company Information Table 51. Amoy Diagnostics Co Business Overview Table 52. Amoy Diagnostics Co Tumor Fluid Biopsy Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Amoy Diagnostics Co Tumor Fluid Biopsy Product Portfolio Table 54. Amoy Diagnostics Co Recent Development Table 55. Berry Genomics Co Company Information Table 56. Berry Genomics Co Business Overview Table 57. Berry Genomics Co Tumor Fluid Biopsy Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Berry Genomics Co Tumor Fluid Biopsy Product Portfolio Table 59. Berry Genomics Co Recent Development Table 60. Genetronhealth Company Information Table 61. Genetronhealth Business Overview Table 62. Genetronhealth Tumor Fluid Biopsy Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Genetronhealth Tumor Fluid Biopsy Product Portfolio Table 64. Genetronhealth Recent Development Table 65. GenoploRare Company Information Table 66. GenoploRare Business Overview Table 67. GenoploRare Tumor Fluid Biopsy Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. GenoploRare Tumor Fluid Biopsy Product Portfolio Table 69. GenoploRare Recent Development Table 70. HaploX Biotechnology Co Company Information Table 71. HaploX Biotechnology Co Business Overview Table 72. HaploX Biotechnology Co Tumor Fluid Biopsy Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. HaploX Biotechnology Co Tumor Fluid Biopsy Product Portfolio Table 74. HaploX Biotechnology Co Recent Development Table 75. New Horizon Health Limited Company Information Table 76. New Horizon Health Limited Business Overview Table 77. New Horizon Health Limited Tumor Fluid Biopsy Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. New Horizon Health Limited Tumor Fluid Biopsy Product Portfolio Table 79. New Horizon Health Limited Recent Development Table 80. Burning Rock Biotech Company Information Table 81. Burning Rock Biotech Business Overview Table 82. Burning Rock Biotech Tumor Fluid Biopsy Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Burning Rock Biotech Tumor Fluid Biopsy Product Portfolio Table 84. Burning Rock Biotech Recent Development Table 85. Guangzhou Wondfo Biotech Company Information Table 86. Guangzhou Wondfo Biotech Business Overview Table 87. Guangzhou Wondfo Biotech Tumor Fluid Biopsy Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Guangzhou Wondfo Biotech Tumor Fluid Biopsy Product Portfolio Table 89. Guangzhou Wondfo Biotech Recent Development Table 90. YZY Biopharma Company Information Table 91. YZY Biopharma Business Overview Table 92. YZY Biopharma Tumor Fluid Biopsy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. YZY Biopharma Tumor Fluid Biopsy Product Portfolio Table 94. YZY Biopharma Recent Development Table 95. Research Programs/Design for This Report Table 96. Authors List of This Report Table 97. Secondary Sources Table 98. Primary Sources List of Figures Figure 1. Tumor Fluid Biopsy Product Image Figure 2. Global Tumor Fluid Biopsy Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Tumor Fluid Biopsy Market Size (2021-2032) & (US$ Million) Figure 4. Global Tumor Fluid Biopsy Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. CTDNA Detection Image Figure 8. CTC Detection Image Figure 9. Other Image Figure 10. Global Tumor Fluid Biopsy Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Tumor Fluid Biopsy Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Tumor Fluid Biopsy Sales Value Share by Type (2021-2032) Figure 13. Hospital Image Figure 14. Third Party Organization Image Figure 15. Other Image Figure 16. Global Tumor Fluid Biopsy Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Tumor Fluid Biopsy Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Tumor Fluid Biopsy Sales Value Share by Application (2021-2032) Figure 19. Global Tumor Fluid Biopsy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Tumor Fluid Biopsy Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Tumor Fluid Biopsy Sales Value (2021-2032) & (US$ Million) Figure 22. North America Tumor Fluid Biopsy Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Tumor Fluid Biopsy Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Tumor Fluid Biopsy Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Tumor Fluid Biopsy Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Tumor Fluid Biopsy Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Tumor Fluid Biopsy Sales Value (2021-2032) & (US$ Million) Figure 28. South America Tumor Fluid Biopsy Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Tumor Fluid Biopsy Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Tumor Fluid Biopsy Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • CTDNA Detection
  • CTC Detection
  • Other
Applications
  • Hospital
  • Third Party Organization
  • Other
Companies covered
  • Cellmax Life
  • Exact Science
  • Amoy Diagnostics Co
  • Berry Genomics Co
  • Genetronhealth
  • GenoploRare
  • HaploX Biotechnology Co
  • New Horizon Health Limited
  • Burning Rock Biotech
  • Guangzhou Wondfo Biotech
  • YZY Biopharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Tumor Fluid Biopsy Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Tumor Fluid Biopsy Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Tumor Fluid Biopsy Market Dynamics
  1. 2.1 Tumor Fluid Biopsy Industry Trends
  2. 2.2 Tumor Fluid Biopsy Industry Drivers
  3. 2.3 Tumor Fluid Biopsy Industry Opportunities and Challenges
  4. 2.4 Tumor Fluid Biopsy Industry Restraints
3 Tumor Fluid Biopsy Market by Company
  1. 3.1 Global Tumor Fluid Biopsy Company Revenue Ranking in 2025
  2. 3.2 Global Tumor Fluid Biopsy Revenue by Company (2021-2026)
  3. 3.3 Global Tumor Fluid Biopsy Company Ranking (2024-2026)
  4. 3.4 Global Tumor Fluid Biopsy Company Manufacturing Base and Headquarters
  5. 3.5 Global Tumor Fluid Biopsy Company Product Type and Application
  6. 3.6 Global Tumor Fluid Biopsy Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Tumor Fluid Biopsy Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Tumor Fluid Biopsy Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Tumor Fluid Biopsy Market by Type
  1. 4.1 Tumor Fluid Biopsy Type Introduction
  2. 4.1.1 CTDNA Detection
  3. 4.1.2 CTC Detection
  4. 4.1.3 Other
  5. 4.2 Global Tumor Fluid Biopsy Sales Value by Type
  6. 4.2.1 Global Tumor Fluid Biopsy Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Tumor Fluid Biopsy Sales Value by Type (2021-2032)
  8. 4.2.3 Global Tumor Fluid Biopsy Sales Value Share by Type (2021-2032)
5 Tumor Fluid Biopsy Market by Application
  1. 5.1 Tumor Fluid Biopsy Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Third Party Organization
  4. 5.1.3 Other
  5. 5.2 Global Tumor Fluid Biopsy Sales Value by Application
  6. 5.2.1 Global Tumor Fluid Biopsy Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Tumor Fluid Biopsy Sales Value by Application (2021-2032)
  8. 5.2.3 Global Tumor Fluid Biopsy Sales Value Share by Application (2021-2032)
6 Tumor Fluid Biopsy Regional Value Analysis
  1. 6.1 Global Tumor Fluid Biopsy Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Tumor Fluid Biopsy Sales Value by Region (2021-2032)
  3. 6.2.1 Global Tumor Fluid Biopsy Sales Value by Region: 2021-2026
  4. 6.2.2 Global Tumor Fluid Biopsy Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Tumor Fluid Biopsy Sales Value (2021-2032)
  7. 6.3.2 North America Tumor Fluid Biopsy Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Tumor Fluid Biopsy Sales Value (2021-2032)
  10. 6.4.2 Europe Tumor Fluid Biopsy Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Tumor Fluid Biopsy Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Tumor Fluid Biopsy Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Tumor Fluid Biopsy Sales Value (2021-2032)
  16. 6.6.2 South America Tumor Fluid Biopsy Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Tumor Fluid Biopsy Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Tumor Fluid Biopsy Sales Value Share by Country, 2025 VS 2032
7 Tumor Fluid Biopsy Country-level Value Analysis
  1. 7.1 Global Tumor Fluid Biopsy Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Tumor Fluid Biopsy Sales Value by Country (2021-2032)
  3. 7.2.1 Global Tumor Fluid Biopsy Sales Value by Country (2021-2026)
  4. 7.2.2 Global Tumor Fluid Biopsy Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Tumor Fluid Biopsy Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Tumor Fluid Biopsy Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Tumor Fluid Biopsy Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Cellmax Life
  2. 8.1.1 Cellmax Life Company Information
  3. 8.1.2 Cellmax Life Business Overview
  4. 8.1.3 Cellmax Life Tumor Fluid Biopsy Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Cellmax Life Tumor Fluid Biopsy Product Portfolio
  6. 8.1.5 Cellmax Life Recent Developments
  7. 8.2 Exact Science
  8. 8.2.1 Exact Science Company Information
  9. 8.2.2 Exact Science Business Overview
  10. 8.2.3 Exact Science Tumor Fluid Biopsy Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Exact Science Tumor Fluid Biopsy Product Portfolio
  12. 8.2.5 Exact Science Recent Developments
  13. 8.3 Amoy Diagnostics Co
  14. 8.3.1 Amoy Diagnostics Co Company Information
  15. 8.3.2 Amoy Diagnostics Co Business Overview
  16. 8.3.3 Amoy Diagnostics Co Tumor Fluid Biopsy Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Amoy Diagnostics Co Tumor Fluid Biopsy Product Portfolio
  18. 8.3.5 Amoy Diagnostics Co Recent Developments
  19. 8.4 Berry Genomics Co
  20. 8.4.1 Berry Genomics Co Company Information
  21. 8.4.2 Berry Genomics Co Business Overview
  22. 8.4.3 Berry Genomics Co Tumor Fluid Biopsy Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Berry Genomics Co Tumor Fluid Biopsy Product Portfolio
  24. 8.4.5 Berry Genomics Co Recent Developments
  25. 8.5 Genetronhealth
  26. 8.5.1 Genetronhealth Company Information
  27. 8.5.2 Genetronhealth Business Overview
  28. 8.5.3 Genetronhealth Tumor Fluid Biopsy Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Genetronhealth Tumor Fluid Biopsy Product Portfolio
  30. 8.5.5 Genetronhealth Recent Developments
  31. 8.6 GenoploRare
  32. 8.6.1 GenoploRare Company Information
  33. 8.6.2 GenoploRare Business Overview
  34. 8.6.3 GenoploRare Tumor Fluid Biopsy Revenue and Gross Margin (2021-2026)
  35. 8.6.4 GenoploRare Tumor Fluid Biopsy Product Portfolio
  36. 8.6.5 GenoploRare Recent Developments
  37. 8.7 HaploX Biotechnology Co
  38. 8.7.1 HaploX Biotechnology Co Company Information
  39. 8.7.2 HaploX Biotechnology Co Business Overview
  40. 8.7.3 HaploX Biotechnology Co Tumor Fluid Biopsy Revenue and Gross Margin (2021-2026)
  41. 8.7.4 HaploX Biotechnology Co Tumor Fluid Biopsy Product Portfolio
  42. 8.7.5 HaploX Biotechnology Co Recent Developments
  43. 8.8 New Horizon Health Limited
  44. 8.8.1 New Horizon Health Limited Company Information
  45. 8.8.2 New Horizon Health Limited Business Overview
  46. 8.8.3 New Horizon Health Limited Tumor Fluid Biopsy Revenue and Gross Margin (2021-2026)
  47. 8.8.4 New Horizon Health Limited Tumor Fluid Biopsy Product Portfolio
  48. 8.8.5 New Horizon Health Limited Recent Developments
  49. 8.9 Burning Rock Biotech
  50. 8.9.1 Burning Rock Biotech Company Information
  51. 8.9.2 Burning Rock Biotech Business Overview
  52. 8.9.3 Burning Rock Biotech Tumor Fluid Biopsy Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Burning Rock Biotech Tumor Fluid Biopsy Product Portfolio
  54. 8.9.5 Burning Rock Biotech Recent Developments
  55. 8.10 Guangzhou Wondfo Biotech
  56. 8.10.1 Guangzhou Wondfo Biotech Company Information
  57. 8.10.2 Guangzhou Wondfo Biotech Business Overview
  58. 8.10.3 Guangzhou Wondfo Biotech Tumor Fluid Biopsy Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Guangzhou Wondfo Biotech Tumor Fluid Biopsy Product Portfolio
  60. 8.10.5 Guangzhou Wondfo Biotech Recent Developments
  61. 8.11 YZY Biopharma
  62. 8.11.1 YZY Biopharma Company Information
  63. 8.11.2 YZY Biopharma Business Overview
  64. 8.11.3 YZY Biopharma Tumor Fluid Biopsy Revenue and Gross Margin (2021-2026)
  65. 8.11.4 YZY Biopharma Tumor Fluid Biopsy Product Portfolio
  66. 8.11.5 YZY Biopharma Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst